The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy.
Jäger
W
W
Institute of Pharmaceutical Chemistry, University of Vienna, Austria.
Gehring
E
E
Hagenauer
B
B
Aust
S
S
Senderowicz
A
A
Thalhammer
T
T
D018528:ATP-Binding Cassette Transporters; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics*; D002352:Carrier Proteins / Q000494:pharmacology*; D004195:Disease Models, Animal; D004347:Drug Interactions; D005419:Flavonoids / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics*; D006932:Hyperbilirubinemia / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D010880:Piperidines / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
D018528:ATP-Binding Cassette Transporters; C423013:Abcc2 protein, rat; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D005419:Flavonoids; D010880:Piperidines; C077990:alvocidib